Please assess the completion status of the following clinical trial:

Trial Title: Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult ≥18 years~* HIV-1 infection~* Infection to genotype 1 HCV only~* Patients must have received at least 12 weeks of treatment with Peg-Interferon alfa 2a ≥ 135 µg / once weekly or Peg-Interferon alfa 2b ≥ 1,0 µg/kg/ once weekly + Ribavirin ≥ 600 mg daily and must have failed to treatment.~* Anti-HCV treatment stopped for at least 6 months~* Patients must be already treated at screen since at least 3 months with a stable combination of antiretroviral treatment as following:~  * Either tenofovir - emtricitabine, and atazanavir in combination with ritonavir~ * Or tenofovir - emtricitabine, and raltegravir~ * If patients cannot receive neither of the two antiretroviral regimens proposed, for virologic, safety or toxicity reasons, patients could receive any effective antiretroviral therapy including : tenofovir, emtricitabine, lamivudine, atazanavir alone or in combination with ritonavir, raltegravir, abacavir. These patients are not allowed to take part in the pharmacokinetic sub-study.~* CD4 \> 200/mm3 et \>15%, at screen~* HIV-RNA \< 50 copies/ml since at least 6 months at screen~* ≥ 40 Kg and ≤ 125 Kg~* Patients with any fibrosis grade. Proportion of F4 subjects should not excess 50% of the overall subjects.~* Male and female subjects must agree to use acceptable methods of contraception 1 month prior to starting the study treatment and to continue until 7 months after the last doses of study drugs for male subjects and their partner(s), 4 months for female subjects.~* Subjects must be willing to give written informed consent for principal study (signed at least at screen visit and prior to any study investigation)and + for the pharmacokinetic sub-study (for the concerned centers).~* Subjects must be willing to give written informed consent for biological collection.~* Subjects must be willing to give written informed consent for treatment of genetics data.~* Subjects affiliated or beneficiary to a medical insurance.~Exclusion Criteria:~History:~* Patients with cirrhosis (F4) and nul responders to prior treatment~* Cirrhosis classified Child-Pugh B or C or history of decompensated cirrhosis of the liver. If Child A classification, significant varicose veins (grade 2 or 3) observed with a fibroscopy realized for \< 3 years.~* History of ocular neuritis, retinal disorders, transplant~* Opportunistic infections (classification C), active or occurred within the 6 months prior to baseline.~* History of neoplasia within the last 5 years, except cutaneous basocellular carcinoma, recovering Kaposi's sarcoma, in situ cervical or anal canal cancer.~Current condition:~* Co-infection with Hepatitis B virus~* Pregnancy and lactation~* Cardiac or severe pulmonary disease~* Untreated dysthyroidism~* Autoimmune disease contraindicating to an interferon treatment~* Severe haemoglobinopathies~* Any condition needing a systemic corticotherapy or an immunosuppressive treatment~* Evolutive current malignancy, including hepatocarcinoma which should be specifically controlled prior to baseline.~* Alcohol consumption which may disturb the study participation according to the investigator~* Drug addiction which may disturb the study participation according to the investigator. Patients taking part to a substitution program with methadone or buprenorphine are allowed to be enrolled in the study.~Biological criteria:~• Haemoglobin \< 12 g/dL (female) or \< 13g/dL (male), Platelets \< 90 000/mm3, Neutrophil count \< 1500/mm3, Renal failure defined as creatinine clearance \< 50ml/min, Uncontrolled thyroid function, HbA1c ≥ 7% in case of diabetes~Criteria related to study drugs~* Contra-indication to Ribavirin, interferon treatment including psychiatric contra-indications.~* History of discontinuation for intolerance to anti-HCV treatment.Patients with a history of discontinuation for intolerance, especially anaemia or leuconeutropenia, and who were not treated with hematopoietic growth factor, are eligible~* Concomitant medication which may interfere with Boceprevir, atazanavir, ritonavir and raltegravir pharmacokinetic~* St.John's-wort consumption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Boceprevir, PegIFN alfa 2b, Ribavirin (Type: EXPERIMENTAL): Standard Treatment :~* Peg-Interferon (PegIFN) alfa 2b by subcutaneous injection 1,5 µg/kg/week~* Ribavirin capsules 200mg: dosage delivered in weight categories (\< 65 kg: 800 mg ; 65-80 kg: 1000 mg; 81-105 kg: 1200mg; \> 105 kg: 1400mg)~Three-drug-regimen:~* Peg-Interferon alfa 2b by subcutaneous injection 1,5 µg/kg/week~* Ribavirin capsules 200mg: dosage delivered in weight categories like in standard treatment~* Boceprevir tablets 200mg: 800 mg 3 times a day (2400 mg/j) with food

Based on this trial design, predict the completion outcome and termination type (if applicable).